B lymphocyte stimulator (BLyS; also known as B cell activating factor (BAFF)) plays a key role in peripheral B cell tolerance. Mounting evidence indicates that B cell tolerance can be either broken or modulated by deliberately manipulating BLyS levels, and belimumab, a BLyS-neutralizing antibody, was recently approved for the treatment of systemic lupus erythematosus (SLE). Thus, intense investigation has focused on understanding how therapeutics targeting BLyS may work, and accumulating evidence suggests multiple points of action. BLyS signaling, in conjunction with B cell receptor (BCR) signaling, determines the size and quality of the mature primary B cell compartment. Moreover, BLyS family members play roles in antigen-experienced B cell selection and differentiation. Together, these findings have implications for the continued development of novel therapeutics that target BLyS.
ZhaoLDLiYSmithMFJr. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus2013; 19: 1534–1549.
2.
StohlW. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther2013; 12: 111–111.
3.
Landolt-MarticorenaCWitherRReichH. Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus. J Rheumatol2011; 38: 642–651.
4.
KhareSDSarosiIXiaXZ. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A2000; 97: 3370–3375.
5.
MackayFSilveiraPABrinkR. B cells and the BAFF/APRIL axis: Fast-forward on autoimmunity and signaling. Curr Opin Immunol2007; 19: 327–336.
6.
FletcherCAGroomJRWoehlBLeungHMackayCMackayF. Development of autoimmune nephritis in genetically asplenic and splenectomized BAFF transgenic mice. J Autoimmun2011; 36: 125–134.
7.
StohlWJacobNGuoSMorelL. Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum2013; 62: 2432–2442.
8.
MackayFWoodcockSALawtonP. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med1999; 190: 1697–1710.
9.
CancroMPD'CruzDPKhamashtaMA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest2009; 119: 1066–1073.
10.
DavidsonA. Targeting BAFF in autoimmunity. Curr Opin Immunol2013; 22: 732–739.
11.
StohlWScholzJLCancroMP. Targeting BLyS in rheumatic disease: The sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol2011; 23: 305–310.
12.
LamoreR IIIParmarSPatelKHilasO. Belimumab (benlysta): A breakthrough therapy for systemic lupus erythematosus. P & T2012; 37: 212–226.
13.
MillerJPStadanlickJECancroMP. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol2006; 176: 6405–6410.
14.
LiuZDavidsonA. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res2011; 317: 1270–1277.
15.
ScholzJLLuning PrakETCancroMP. Targeting the BLyS family in autoimmunity: A tale of mouse and man. Clin Invest2011; 1: 951–967.
16.
YurasovSNussenzweigMC. Regulation of autoreactive antibodies. Curr Opin Rheumatol2007; 19: 421–426.
17.
WardemannHNussenzweigMC. B-cell self-tolerance in humans. Adv Immunol2007; 95: 83–110.
18.
EriksonJRadicMZCamperSAHardyRRCarmackCWeigertM. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature1991; 349: 331–334.
19.
HannumLGNiDHabermanAMWeigertMGShlomchikMJ. A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: Implications for the origins of autoantibodies in autoimmune disease. J Exp Med1996; 184: 1269–1278.
20.
NashiEWangYDiamondB. The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol2013; 42: 543–550.
21.
DornerTGieseckeCLipskyPE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther2011; 13: 243–254–243–254.
22.
MeffreEWardemannH. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol2008; 20: 632–638.
23.
MackayFSchneiderP. Cracking the BAFF code. Nat Rev Immunol2009; 9: 491–502.
24.
OropalloMAKieferKMarshak-RothsteinACancroMP. Beyond transitional selection: New roles for BLyS in peripheral tolerance. Drug Dev Res2011; 72: 779–787.
25.
CancroMP. The BLyS family of ligands and receptors: An archetype for niche-specific homeostatic regulation. Immunol Rev2004; 202: 237–249.
26.
BossenCSchneiderP. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol2006; 18: 263–275.
27.
HuardBMcKeeTBosshardC. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest2008; 118: 2887–2895.
28.
RickertRCJellusovaJMileticAV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev2011; 244: 115–133.
29.
CrowleyJEScholzJLQuinnWJ III. Homeostatic control of B lymphocyte subsets. Immunol Res2008; 42: 75–83.
30.
TremlJFHaoYStadanlickJECancroMP. The BLyS family: Toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys2009; 53: 1–16.
31.
StadanlickJEKailehMKarnellFG. Tonic B cell antigen receptor signals supply an NF-kappa B substrate for prosurvival BLyS signaling. Nat Immunol2008; 9: 1379–1387.
32.
BensonMJDillonSRCastigliE. Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol2008; 180: 3655–3659.
33.
O'ConnorBPRamanVSEricksonLD. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med2004; 199: 91–98.
34.
ScholzJLCrowleyJETomaykoMM. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A2008; 105: 15 517–15522.
35.
StohlWHiepeFLatinisKM. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum2012; 64: 2328–2337.
36.
Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012; 39: 1632–1640.
37.
GorelikLGilbrideKDoblesMKalledSLZandmanDScottML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med2003; 198: 937–945.
38.
TangyeSGBryantVLCussAKGoodKL. BAFF, APRIL and human B cell disorders. Semin Immunol2006; 18: 305–317.
39.
BossenCTardivelAWillenL. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol2011; 41: 787–797.
40.
BossenCCacheroTGTardivelA. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood2008; 111: 1004–1012.
41.
KalininaODoyle-CooperCMMiksanekJMengWPrakELWeigertMG. Alternative mechanisms of receptor editing in autoreactive B cells. Proc Natl Acad Sci U S A2011; 108: 7125–7130.
42.
PelandaRTorresRM. Receptor editing for better or for worse. Curr Opin Immunol2006; 18: 184–190.
43.
PelandaRTorresRM. Central B-cell tolerance: Where selection begins. Cold Spring Harb Perspect Biol2012; 4: a007146–a007146.
44.
OsmondDG. Proliferation kinetics and the lifespan of B cells in central and peripheral lymphoid organs. Curr Opin Immunol1991; 3: 179–185.
45.
AllmanDMFergusonSELentzVMCancroMP. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol1993; 151: 4431–4444.
46.
OsmondDG. The turnover of B-cell populations. Immunol Today1993; 14: 34–37.
47.
RolinkAGAnderssonJMelchersF. Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity. Eur J Immunol1998; 28: 3738–3748.
48.
VerkoczyLKMartenssonASNemazeeD. The scope of receptor editing and its association with autoimmunity. Curr Opin Immunol2004; 16: 808–814.
49.
Azulay-DebbyHMelamedD. B cell receptor editing in tolerance and autoimmunity. Front Biosci2007; 12: 2136–2147.
50.
HsuBLHarlessSMLindsleyRCHilbertDMCancroMP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol2002; 168: 5993–5996.
51.
LoderFMutschlerBRayRJ. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med1999; 190: 75–89.
52.
AllmanDLindsleyRCDeMuthWRuddKShintonSAHardyRR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol2001; 167: 6834–6840.
53.
SmithSHRethM. Perspectives on the nature of BCR-mediated survival signals. Mol Cell2004; 14: 696–697.
54.
MonroeJGDorshkindK. Fate decisions regulating bone marrow and peripheral B lymphocyte development. Adv Immunol2007; 95: 1–50.
55.
WangHClarkeSH. Evidence for a ligand-mediated positive selection signal in differentiation to a mature B cell. J Immunol2003; 171: 6381–6388.
56.
MonroeJGBannishGFuentes-PananaEM. Positive and negative selection during B lymphocyte development. Immunol Res2003; 27: 427–442.
57.
HarlessSMLentzVMSahAP. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol2001; 11: 1986–1989.
58.
ThompsonJSSchneiderPKalledSL. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med2000; 192: 129–135.
59.
YanMBradyJRChanB. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol2001; 11: 1547–1552.
60.
BattenMGroomJCacheroTG. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med2000; 192: 1453–1466.
61.
LentzVMCancroMPNasholdFEHayesCE. Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse. J Immunol1996; 157: 598–606.
62.
LentzVMHayesCECancroMP. Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. J Immunol1998; 160: 3743–3747.
63.
SasakiYCasolaSKutokJLRajewskyKSchmidt-SupprianM. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol2004; 173: 2245–2252.
64.
StadanlickJECancroMP. BAFF and the plasticity of peripheral B cell tolerance. Curr Opin Immunol2008; 20: 158–161.
65.
LesleyRXuYKalledSL. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity2004; 20: 441–453.
66.
ThienMPhanTGGardamS. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity2004; 20: 785–798.
67.
HondowiczBDAlexanderSTQuinnWJ III. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int Immunol2007; 19: 465–475.
68.
CancroMP. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol2009; 9: 657–661.
69.
SutterJAKwan-MorleyJDunhamJ. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol2008; 126: 282–290.
70.
PalanichamyABarnardJZhengB. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol2009; 182: 5982–5993.
71.
AnolikJHFriedbergJWZhengB. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol2007; 122: 139–145.
72.
LeandroMJCambridgeGEhrensteinMREdwardsJC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum2006; 54: 613–620.
73.
WarnatzKSalzerURizziM. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A2009; 106: 13 945–13950.
74.
CarterRHZhaoHLiuX. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum2005; 52: 3943–3954.
75.
KreuzalerMRauchMSalzerU. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol2012; 188: 497–503.
76.
SanzIYasothanUKirkpatrickP. Belimumab. Nat Rev Drug Discov2011; 10: 335–336.
77.
YurasovSWardemannHHammersenJ. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med2005; 201: 703–711.
78.
YurasovSTillerTTsuijiM. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med2006; 203: 2255–2261.
79.
StohlWMetyasSTanSM. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum2003; 48: 3475–3486.
80.
DillonSRHarderBLewisKB. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther2013; 12: R48–R48.
81.
AnolikJHBarnardJCappioneA. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum2004; 50: 3580–3590.
82.
PetriMStohlWChathamW. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum2008; 58: 2453–2459.
83.
TremlLSQuinnWJ IIITremlJFScholzJLCancroMP. Manipulating B cell homeostasis: A key component in the advancement of targeted strategies. Arch Immunol Ther Exp (Warsz)2008; 56: 153–164.
84.
ScholzJLCancroMP. Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunol Lett2012; 143: 2–8.
85.
CambridgeGIsenbergDAEdwardsJC. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis2008; 67: 1011–1016.
86.
LavieFMiceli-RichardCIttahMSellamJGottenbergJEMarietteX. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis2007; 66: 700–703.
87.
CancroMP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis2006; 65: S34–S36.
88.
WardemannHYurasovSSchaeferAYoungJWMeffreENussenzweigMC. Predominant autoantibody production by early human B cell precursors. Science2003; 301: 1374–1377.
89.
ZengDLeeMKTungJBrendolanAStroberS. Cutting edge: A role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol2000; 164: 5000–5004.
90.
GrimaldiCMMichaelDJDiamondB. Cutting edge: Expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol2001; 167: 1886–1890.
91.
JegerlehnerAMaurerPBessaJHintonHJKopfMBachmannMF. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol2007; 178: 2415–2420.
92.
HerveMIsnardiINgYS. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med2007; 204: 1583–1593.
93.
ChanTDBrinkR. Affinity-based selection and the germinal center response. Immunol Rev2012; 247: 11–23.
94.
ElguetaRDe VriesVCNoelleRJ. The immortality of humoral immunity. Immunol Rev2013; 236: 139–150.
95.
ShlomchikMJWeiselF. Germinal center selection and the development of memory B and plasma cells. Immunol Rev2012; 247: 52–63.
96.
ZaheenAMartinA. Activation-induced cytidine deaminase and aberrant germinal center selection in the development of humoral autoimmunities. Am J Pathol2011; 178: 462–471.
97.
WangHShlomchikMJ. Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice. J Exp Med1999; 190: 639–649.
98.
HaoZDuncanGSSeagalJ. Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity2008; 29: 615–627.
99.
NananRStrobelPHaasJPMarxAKrethHW. Autoimmune lymphoproliferative syndrome associated with severe humoral immunodeficiency and monoclonal gammopathy. Ann Hematol2002; 81: 332–335.
100.
InfanteAJBrittonHADeNapoliT. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J Pediatr1998; 133: 629–633.
101.
JacksonCEFischerREHsuAP. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet1999; 64: 1002–1014.
102.
Van EijkMDefranceTHenninoADe GrootC. Death-receptor contribution to the germinal-center reaction. Trends Immunol2001; 22: 677–682.
103.
CastigliEScottSDedeogluF. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A2004; 101: 3903–3908.
104.
VoraKAWangLCRaoSP. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol2003; 171: 547–551.
105.
RahmanZSRaoSPKalledSLManserT. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med2003; 198: 1157–1169.
106.
RahmanZSManserT. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J Immunol2004; 173: 6179–6188.
107.
MillerDJHansonKDCarmanJAHayesCE. A single autosomal gene defect severely limits IgG but not IgM responses in B lymphocyte-deficient A/WySnJ mice. Eur J Immunol1992; 22: 373–379.
MantchevGTCortesaoCSRebrovichMCascalhoMBramRJ. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J Immunol2007; 179: 2282–2288.
110.
HeBSantamariaRXuW. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol2013; 11: 836–845.
111.
Von BulowGUVan DeursenJMBramRJ. Regulation of the T-independent humoral response by TACI. Immunity2001; 14: 573–582.
112.
DarceJRArendtBKWuXJelinekDF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol2007; 179: 7276–7286.
113.
WinterOMoserKMohrE. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood2013; 116: 1867–1875.
114.
BelnoueETougneCRochatAFLambertPHPinschewerDDSiegristCA. Homing and adhesion patterns determine the cellular composition of the bone marrow plasma cell niche. J Immunol2012; 188: 1283–1291.
115.
VarfolomeevEKischkelFMartinF. APRIL-deficient mice have normal immune system development. Mol Cell Biol2004; 24: 997–1006.
116.
RamanujamMWangXHuangW. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest2006; 116: 724–734.
117.
CarbonattoMYuPBertolinoM. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci2008; 105: 200–210.
118.
BelnoueEPihlgrenMMcGahaTL. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood2008; 111: 2755–2764.
119.
TremlLSCrowleyJECancroMP. BLyS receptor signatures resolve homeostatically independent compartments among naive and antigen-experienced B cells. Semin Immunol2006; 18: 297–304.
120.
PallikkuthSKanthikeelSPSilvaSYFischlMPahwaRPahwaS. Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients. J Allergy Clin Immunol2011; 128: 1279–1285.
121.
EttingerRSimsGPRobbinsR. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol2007; 178: 2872–2882.
122.
AndersonSMTomaykoMMShlomchikMJ. Intrinsic properties of human and murine memory B cells. Immunol Rev2006; 211: 280–294.
123.
ReynaudCADescatoireMDoganIHuetzFWellerSWeillJC. IgM memory B cells: A mouse/human paradox. Cell Mol Life Sci2012; 69: 1625–1634.
124.
TangyeSGTarlintonDM. Memory B cells: effectors of long-lived immune responses. Eur J Immunol2009; 39: 2065–2075.
125.
PauliNTHenry DunandCJWilsonPC. Exploiting human memory B cell heterogeneity for improved vaccine efficacy. Front Immunol2011; 2: 77: 1–12.
126.
TillerTTsuijiMYurasovSVelinzonKNussenzweigMCWardemannH. Autoreactivity in human IgG+ memory B cells. Immunity2007; 26: 205–213.
127.
HuangWMoisiniIBethunaickanR. BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol2011; 187: 6571–6580.
128.
TillerTKoferJKreschelC. Development of self-reactive germinal center B cells and plasma cells in autoimmune Fc gammaRIIB-deficient mice. J Exp Med2013; 207: 2767–2778.
129.
VuyyuruRMohanCManserTRahmanZS. The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints. J Immunol2009; 183: 5716–5727.
130.
CappioneA IIIAnolikJHPugh-BernardA. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest2005; 115: 3205–3216.
131.
JacobiAMOdendahlMReiterK. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum2003; 48: 1332–1342.
132.
MietznerBTsuijiMScheidJ. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci U S A2008; 105: 9727–9732.
133.
JacobiAMReiterKMackayM. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum2008; 58: 1762–1773.
134.
IlleiGGShirotaYYarboroCH. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum2013; 62: 542–552.
135.
GrammerACSlotaRFischerR. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest2003; 112: 1506–1520.m.
136.
CaleroINietoJASanzI. B cell therapies for rheumatoid arthritis: Beyond B cell depletion. Rheum Dis Clin North Am2013; 36: 325–343.
137.
MerrillJTNeuweltCMWallaceDJ. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum2013; 62: 222–233.
138.
LeandroMJCambridgeGEdwardsJCEhrensteinMRIsenbergDA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford)2005; 44: 1542–1545.
139.
JacobiAMHuangWWangT. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum2013; 62: 201–210.
Dall'EraMChakravartyEWallaceD. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum2007; 56: 4142–4150.
142.
Pena-RossiCNasonovEStanislavM. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus2009; 18: 547–555.
143.
GenestierLTaillardetMMondierePGheitHBellaCDefranceT. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol2007; 178: 7779–7786.
144.
MartinFOliverAMKearneyJF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity2001; 14: 617–629.
145.
GuinamardROkigakiMSchlessingerJRavetchJV. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol2000; 1: 31–36.
GroomJRFletcherCAWaltersSN. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med2007; 204: 1959–1971.
148.
MedzhitovRPreston-HurlburtPJanewayCAJr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature1997; 388: 394–397.
BoothJWilsonHJimboSMutwiriG. Modulation of B cell responses by Toll-like receptors. Cell Tissue Res2011; 343: 131–140.
151.
AlexopoulouLHoltACMedzhitovRFlavellRA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature2001; 413: 732–738.
152.
DieboldSSKaishoTHemmiHAkiraSReis e SousaC. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science2004; 303: 1529–1531.
153.
HemmiHTakeuchiOKawaiT. A Toll-like receptor recognizes bacterial DNA. Nature2000; 408: 740–745.
154.
HeilFHemmiHHochreinH. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science2004; 303: 1526–1529.
155.
LeadbetterEARifkinIRHohlbaumAMBeaudetteBCShlomchikMJMarshak-RothsteinA. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature2002; 416: 603–607.
156.
VigliantiGALauCMHanleyTMMikoBAShlomchikMJMarshak-RothsteinA. Activation of autoreactive B cells by CpG dsDNA. Immunity2003; 19: 837–847.
157.
UccelliniMBBusconiLGreenNM. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J Immunol2008; 181: 5875–5884.
158.
LauCMBroughtonCTaborAS. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med2005; 202: 1171–1177.
159.
ChristensenSRShupeJNickersonKKashgarianMFlavellRAShlomchikMJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity2006; 25: 417–428.
160.
ChristensenSRKashgarianMAlexopoulouLFlavellRAAkiraSShlomchikMJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med2005; 202: 321–331.
161.
NickersonKMChristensenSRShupeJ. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol2013; 184: 1840–1848.
162.
CohenPLCaricchioRAbrahamV. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med2002; 196: 135–140.
163.
HanayamaRTanakaMMiyasakaK. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science2004; 304: 1147–1150.
164.
TremlLSCarlessoGHoekKL. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol2007; 178: 7531–7539.
165.
KimJGrossJADillonSRMinJKElkonKB. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation. Autoimmunity2011; 44: 69–81.
166.
ObukhanychTVNussenzweigMC. T-independent type II immune responses generate memory B cells. J Exp Med2006; 203: 305–310.
